Hims & Hers Health shares fell over 11% after an FDA advisory panel voted 7 to 6 against adding Emideltide to the compounding 503A Bulks List.
THE IMPACT: The narrow rejection raises near-term regulatory hurdles for compounding pharmacy operators looking to offer customized peptide therapies.
FUNDAMENTALS: Core operations remain strong, supported by $2.37B in total revenue and a high 72.92% gross margin.
THE RATING: Regulatory uncertainty keeps the Seeking Alpha Quant score at a neutral HOLD.
Will $HIMS overcome these regulatory hurdles with its expanded pharmacy compounding strategy?
My mom paid off her house in 2003.
Thought that was it. Thought she was done. Thought it was finally hers.
Property taxes were $1,800 a year back then.
She’s retired now. Fixed income. Same house. Same neighborhood.
Property taxes are $24,000 a year.
That’s $2,000 a month.
On a house she already paid for.
She’s 71 years old and the government sends her a bill every year just to stay in her own home.
You never really own anything in America.
You just make payments to a different landlord.
was in my local yarn shop and the girl who worked there pointed out my shenron plush on my bag, complimented and said she had one too. mine was a gift from one of those merch boxes 10 years ago, and she got hers from the same box! i met another shenron plush wielder in the wild
Hims & Hers went from a scrappy startup to a telehealth powerhouse worth almost $11 billion in just a few years.
@g0ingmad explains how the company became the king of knockoff weight-loss drugs